Fulvestrant 500mg + Palbociclib 125mg + Goserelin 3.6 MG + Placebos
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Neoplasm Female
Conditions
Breast Neoplasm Female
Trial Timeline
Dec 20, 2017 → Jul 20, 2021
NCT ID
NCT03447132About Fulvestrant 500mg + Palbociclib 125mg + Goserelin 3.6 MG + Placebos
Fulvestrant 500mg + Palbociclib 125mg + Goserelin 3.6 MG + Placebos is a phase 3 stage product being developed by AstraZeneca for Breast Neoplasm Female. The current trial status is completed. This product is registered under clinical trial identifier NCT03447132. Target conditions include Breast Neoplasm Female.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03447132 | Phase 3 | Completed |
Competing Products
20 competing products in Breast Neoplasm Female